Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease

@article{Liu2015NeuroprotectiveEO,
  title={Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease},
  author={W P Liu and Jaishree Jalewa and M. Sharma and G. Li and L. Li and Christian H{\"o}lscher},
  journal={Neuroscience},
  year={2015},
  volume={303},
  pages={42-50}
}
Glucagon-like peptide 1 (GLP-1) is a growth factor. GLP-1 mimetics are on the market as treatments for type 2 diabetes and are well tolerated. These drugs have shown neuroprotective properties in animal models of neurodegenerative disorders. In addition, the GLP-1 mimetic exendin-4 has shown protective effects in animal models of Parkinson's disease (PD), and a clinical trial in PD patients showed promising first results. Liraglutide and lixisenatide are two newer GLP-1 mimetics which have a… 
Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson’s disease mouse model
TLDR
GLP-1-glu-PAL showed good effects in preventing the MPTP-induced motor impairment, and showed promise as a novel treatment of PD.
Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease.
TLDR
It is demonstrated for the first time that protease resistant oxyntomodulin analogues have neuroprotective effects and shows promise as a novel treatment of Parkinson's disease.
Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model
TLDR
The results demonstrate that the new long- acting GLP-1 analogue semaglutide may be a promising treatment for PD.
A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson′s disease by increasing expression of BNDF
TLDR
Levels of the neuroprotective brain derived neurotropic factor (BDNF) were reduced by MPTP and enhanced by DA-JC1, demonstrating that DA- JC1 shows promise as a novel treatment for PD.
Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease
TLDR
Liraglutide showed no neuroprotective effects in the context of moderate or substantial midbrain dopaminergic neuronal loss and associated functional motor deficits in the rat 6-OHDA lesion model of PD.
A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson’s disease by reducing chronic inflammation in the brain
TLDR
The neuroprotective effects of a novel dual agonist (DA-JC1) in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease (PD) shows promise as a novel treatment of PD.
Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease
TLDR
The data suggest that post-treatment with PT302 provides long-lasting Exendin-4 release and reduces neurodegeneration of nigrostriatal dopaminergic neurons in a 6-hydroxydopamine rat model of PD at a clinically relevant dose.
The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1G93A and TDP-43Q331K transgenic mouse models of ALS
TLDR
Overall, it is found that there is no evidence to support clinical evaluation of liraglutide as a potential candidate for the treatment of ALS.
Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease
TLDR
The relationship between insulin resistance and Parkinson's disease, the implications on pathogenesis and the efforts to reposition GLP-1 agonists as potential treatments for Parkinson’s disease are reviewed.
Neuroprotective effects of liraglutide against inflammation through the AMPK/NF-κB pathway in a mouse model of Parkinson's disease.
TLDR
Results suggest that liraglutide can suppress neuroinflammation, and this effect is mediated through the AMPK/NF-κB signaling pathway.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 38 REFERENCES
Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease
TLDR
The results demonstrate that the GLP-1 receptor agonists liraglutide and lixisenatide show promise as potential drug treatments of AD.
Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.
TLDR
GLP-1 mimetics show great promise as a novel treatment for neurodegenerative conditions because of the substantial body of evidence that these mimetics have neuroprotective and anti-inflammatory effects.
Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
TLDR
It is shown that, in the mouse MPTP PD model, systemic administration of exendin-4 significantly attenuates the loss of substantia nigra pars compacta neurons and the striatal dopaminergic fibers and suggests that exendIn-4 may be a valuable therapeutic agent for neurodegenerative diseases such as PD.
Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease
TLDR
The apparent ability of EX-4 to arrest progression of, or even reverse nigral lesions once established, suggests that pharmacological manipulation of the GLP-1 receptor system could have substantial therapeutic utility in PD.
Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis
TLDR
The results suggest that these novel incretin analogues cross the blood brain barrier and show physiological activity and neurogenesis in the brain, which may be of use as a treatment of neurodegenerative diseases.
MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease.
TLDR
This review summarises advances made in understanding the biochemical events which underlie the remarkable neurotoxic action of MPTP and the relevance of the MPTP model to idiopathic Parkinson's disease is discussed.
The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (mptp) and its relevance to parkinson's disease
TLDR
Differences between common laboratory animals and primates which may account for the differences in sensitivity and selectivity of the actions of MPTP are considered as are other factors which may be involved in the neurotoxicity of this compound.
The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease
TLDR
In APP/PS1 mice, liraglutide prevented memory impairments in object recognition and water maze tasks, and prevented synapse loss and deterioration of synaptic plasticity in the hippocampus, commonly observed in this model, suggesting that GLP-1 analogs represent a novel treatment strategy for Alzheimer's disease.
Neuroprotective Effects of Liraglutide for Stroke Model of Rats
TLDR
This is the first study to demonstrate neuroprotective effects of liraglutide on cerebral ischemia through anti-oxidative effects and VEGF upregulation on a rat stroke model.
Exendin-4 promotes the membrane trafficking of the AMPA receptor GluR1 subunit and ADAM10 in the mouse neocortex
TLDR
It is suggested that GLP-1 facilitates the GluR1 membrane insertion through CREB activation and increases α-secretase activity through ADAM10 membrane trafficking.
...
1
2
3
4
...